Biopharmaceutical company fined for misleading investors

A Colorado-based biopharmaceutical company must pay more than $20 million for misleading investors about the efficacy of a lung cancer drug under development before raising $300 million in a public stock offering
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news